Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 AMeta-analysis

Autor: Shankar-Hari, M, Vale, CL, Godolphin, PJ, Fisher, D, Higgins, JPT, Spiga, F, Savovic, J, Tierney, J, Baron, G, Benbenishty, JS, Berry, LR, Broman, N, Cavalcanti, AB, Colman, R, De Buyser, SL, Derde, LPG, Domingo, P, Omar, SF, Fernandez-Cruz, A, Feuth, T, Garcia, F, Garcia-Vicuna, R, Gonzalez-Alvaro, I, Gordon, AC, Haynes, R, Hermine, O, Horby, PW, Horick, NK, Kumar, K, Lambrecht, BN, Landray, MJ, Leal, L, Lederer, DJ, Lorenzi, E, Mariette, X, Merchante, N, Misnan, NA, Mohan, SV, Nivens, MC, Oksi, J, Perez-Molina, JA, Pizov, R, Porcher, R, Postma, S, Rajasuriar, R, Ramanan, AV, Ravaud, P, Reid, PD, Rutgers, A, Sancho-Lopez, A, Seto, TB, Sivapalasingam, S, Soin, AS, Staplin, N, Stone, JH, Strohbehn, GW, Sunden-Cullberg, J, Torre-Cisneros, J, Tsai, LW, van Hoogstraten, H, van Meerten, T, Veiga, VC, Westerweel, PE, Murthy, S, Diaz, JV, Marshall, JC, Sterne, JAC, Pomar V., Benito N., WHO Rapid Evidence Appraisal COVID

Publikováno v: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

IMPORTANCE Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized for COVID-19 have variously reported benefit, no effect, and harm. OBJECTIVE To estimate the association between administration of IL-6 antagonists compare

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::a2c5c0ab547ccf2be0501d4122d08556
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4406

Pre-hospital transdermal glyceryl trinitrate for transient ischaemic attack: Data from the RIGHT-2 trial.

Autor: Appleton JP; Stroke, Nottingham University Hospitals NHS Trust, Nottingham, UK.; Stroke Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK., Dixon M; Stroke Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK.; East Midlands Ambulance Service NHS Trust, Nottingham, UK., Woodhouse LJ; Stroke Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK., Anderson CS; George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.; George Institute, Peking University Health Science Center, Beijing, China.; Neurology Department, Royal Prince Alfred Hospital, Sydney Health Partners, Sydney, New South Wales, Australia., Ankolekar S; Department of Neurology, King's College Hospital London, London, UK., Cala L; Faculty of Health and Medical Sciences, University of Western Australia, Perth, Western Australia, Australia., England TJ; Stroke Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK., Godolphin PJ; MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK., Krishnan K; Stroke, Nottingham University Hospitals NHS Trust, Nottingham, UK.; Stroke Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK., Mair G; Centre for Clinical Brain Sciences, Edinburgh Imaging and UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK., Muir KW; Institute of Neurology and Psychology, University of Glasgow, Glasgow, UK., Potter J; Bob Champion Research and Education Building, University of East Anglia, Norwich, UK., Price CI; Population Health Sciences Institute, Newcastle University, Newcastle, UK., Randall M; Neurology, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Robinson TG; Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK., Roffe C; Stroke Research in Stoke, School of Medicine, Keele University, Stoke-on-Trent, UK., Rothwell PM; Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK., Sandset EC; Department of Neurology, Oslo University Hospital, Oslo, Norway.; Research and Development, Norwegian Air Ambulance Foundation, Oslo, Norway., Saver JL; Department of Neurology and Comprehensive Stroke Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA., Siriwardena AN; Community and Health Research Unit, University of Lincoln, Lincoln, UK., Wardlaw JM; Centre for Clinical Brain Sciences, Edinburgh Imaging and UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK., Sprigg N; Stroke, Nottingham University Hospitals NHS Trust, Nottingham, UK.; Stroke Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK., Bath PM; Stroke, Nottingham University Hospitals NHS Trust, Nottingham, UK.; Stroke Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK.

Publikováno v: European journal of neurology [Eur J Neurol] 2024 Dec; Vol. 31 (12), pp. e16502. Date of Electronic Publication: 2024 Oct 11.

Nonlinear effects and effect modification at the participant-level in IPD meta-analysis part 1: analysis methods are often substandard.

Autor: Marlin N; Methodology Research Unit, Centre for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University of London, 58 Turner Street, London E1 2AB, UK. Electronic address: n.marlin@qmul.ac.uk., Godolphin PJ; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, 90 High Holborn, London WC1V 6LJ, UK., Hooper RL; Methodology Research Unit, Centre for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University of London, 58 Turner Street, London E1 2AB, UK., Riley RD; Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK., Rogozińska E; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, 90 High Holborn, London WC1V 6LJ, UK.

Publikováno v: Journal of clinical epidemiology [J Clin Epidemiol] 2023 Jul; Vol. 159, pp. 309-318. Date of Electronic Publication: 2023 May 04.

Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.

Autor: Vale CL; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK. Electronic address: claire.vale@ucl.ac.uk., Fisher DJ; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK., Godolphin PJ; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK., Rydzewska LH; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK., Boher JM; Biostatistics Unit, Institut Paoli-Calmettes, Marseille, France., Burdett S; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK., Chen YH; Department of Biostatistics and Computational Biology ECOG-ACRIN Cancer Research Group, Dana-Farber Cancer Institute, Boston, MA, USA., Clarke NW; Department of Surgery and Department of Urology, The Christie and Salford Royal Hospitals, Manchester, UK., Fizazi K; Department of Cancer Medicine, Institut Gustave Roussy, Paris, France., Gravis G; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France., James ND; Institute of Cancer Research, London, UK., Liu G; Department of Urology, Department of Medicine, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA., Matheson D; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK., Murphy L; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK., Oldroyd RE; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK., Parmar MKB; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK., Rogozinska E; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK., Sfumato P; Biostatistics Unit, Institut Paoli-Calmettes, Marseille, France., Sweeney CJ; SAiGENCI, University of Adelaide, Adelaide, SA, Australia., Sydes MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK., Tombal B; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain-la-Neuve, Belgium., White IR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK., Tierney JF; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2023 Jul; Vol. 24 (7), pp. 783-797.

Correction to: The reporting standards of randomised controlled trials in leading medical journals between 2019 and 2020: a systematic review.

Autor: McErlean M; UCLPartners, London, UK., Samways J; Cardiology Department, London North West University, Healthcare NHS Trust, London, UK., Godolphin PJ; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University, College London, London, UK., Chen Y; Institute of Health Informatics, University College London, 222 Euston Road, London NW1 2DA, UK. yang.a.chen@ucl.ac.uk.

Publikováno v: Irish journal of medical science [Ir J Med Sci] 2023 Feb; Vol. 192 (1), pp. 81.